Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of weekly LY3209590 vs once-daily insulin degludec in adults with type 1 diabetes
2021-005892-38Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Insulin efsitora alfa in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline. Started Jul 2022; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2021-005892-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005892-38.